Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 23, 2026
Reporting Period: Fourth quarter ended December 31, 2025
This filing announces the financial results for the fourth quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing serves as a notification of the results announcement. Specific management commentary, guidance, or outlook is located in the attached press release.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in the Form 8-K and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 2025 revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for any updated full-year 2026 guidance or forward-looking statements in the press release.
- Confirm the status of any clinical trials or regulatory approvals mentioned in the full press release.